Antimicrobial-Releasing Implant Substrates for Combating Oral Biofilms: An In Vitro Study

用于对抗口腔生物膜的抗菌释放植入基质:一项体外研究

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Peri-implantitis, a biofilm-associated inflammatory disease, significantly threatens dental implant longevity. Current treatments face limitations due to biofilm robustness. This study evaluates the efficacy of antimicrobial-releasing titanium-silica (Ti/SiO(2)) composite implant systems against multispecies oral biofilms, aiming to advance innovative localized and targeted peri-implantitis prevention and management strategies. MATERIALS AND METHODS: Ti/SiO(2) inserts were engineered with macroporous Ti6Al4V discs produced by additive manufacturing (AM) and a sol-gel-derived mesoporous SiO(2) barrier for controlled antimicrobial release across the discs. Chlorhexidine (CHX), as the gold standard antimicrobial agent in dental practice, was tested for its release efficacy using either a laboratory-prepared chlorhexidine diacetate solution (CHX-DA) or the commercial formulation Corsodyl. Phosphate-buffered saline (PBS) and Brain Heart Infusion-2 (BHI-2) medium served as control solutions. After establishing the CHX-DA release profile, multispecies biofilms were grown on the inserts. The antimicrobial efficacy of the release systems was assessed via viability-qPCR, scanning electron microscopy (SEM), and metabolic acid profiling. All experiments were conducted four times. RESULTS: A mean pore diameter of 5.6 nm was observed for the discs, resulting in a steady drug release rate (≈0.00077 mmol/L CHX-DA/day). The antimicrobial-fed inserts showed less biofilm formation, with ≥ 2 log(10) reductions in viable bacteria compared to controls. CHX-DA and Corsodyl showed effective suppression of pathogenic bacteria and reductions in metabolic acid production. SEM analysis revealed morphological changes in bacterial cells on treated surfaces. CONCLUSION: Antimicrobial-releasing Ti/SiO(2) implant discs demonstrated sustained efficacy in biofilm prevention and treatment, indicating their feasibility as a future strategy for peri-implantitis management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。